Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $22.
Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $22.